BI's Spiriva HandiHaler Joins GSK's Advair Diskus In COPD Exacerbations Reduction Claim
This article was originally published in The Pink Sheet Daily
Executive Summary
The steroid-free, long-acting anticholinergic gains another selling point as others ready drugs for the $7 billion to $8 billion COPD market.